Skip to main content
. 2019 Oct 22;71(6):454–458. doi: 10.1016/j.ihj.2019.10.003

Table 2.

Baseline clinical and echocardiographic characteristics and immediate results in both groups.

Variable Group 1 (n = 42) Group 2 (n = 126) p value
Age -yr – mean ± SD 39.5 ± 10.5 46.6 ± 13 0.005
Atrial fibrillation – no. (%) 6 (14.3) 55 (32.7) 0.007
Female gender – no. (%) 36 (85.7) 110 (87.6) 1.00
NYHA FC II – no. (%) 28 (66.6) 77 (61.1) 0.89
NYHA FC III – no. (%) 13 (30.9) 44 (34.9) 0.89
NYHA FC IV – no. (%) 1 (2,3) 5 (3.9) 0.89
Pre-PMV MVA - cm2 (IQR 25–75%) 0.90 (0.83–1.00) 0.90 (0.81–1.00) NS
ES – value (IQR 25–75%) 6 (5–7) 8 (6–9) 0.002
ES > 8 – no. (%) 7 (16.6) 55 (32.7) 0.003
sPAP pre-PMV – mmHg (IQR 25–75%) 47 (34–59) 42 (35–50) 0.07
MVG – mmHg (IQR 25–75%) 11.0 (9.-16) 11 (9–14) NS
Immediate success – no. (%) 40 (95.2) 96 (76.2) 0.01
Post-PMV MVA – cm2 (IQR 25–75%) 1.82 (1.6–2.0) 1.67 (1.44–1.97) 0.02
MR post-PMV – no. (%) 34 (80.9) 117 (92.8) 0.04

Group 1 = minimal valve calcification, Group 2 = moderate to severe valve calcification.

NYHA FC= New York Heart Association functional class; PMV = percutaneous mitral valvuloplasty; MVA = mitral valve area; IQR = interquartile range; ES = echocardiographic score; sPAP = systolic pulmonary artery pressure; MVG = mean valve gradient; MR = mitral regurgitation.